Introduction
============

A complete pathologic response of breast cancer after neoadjuvant chemotherapy (NAC) appears to be particularly favorable at 5 years in patients with the least evidence of a tumor in the breast or lymph nodes after therapy ([@b1-or-35-05-2592],[@b2-or-35-05-2592]). The National Surgical Adjuvant Breast and Bowel Project trials distinguished between the absence and presence of residual invasive carcinoma in the breast and noted that long-term outcome was also dependent on the extent of lymph node involvement ([@b1-or-35-05-2592]). Axillary lymph node metastasis after NAC in breast cancer is a poor prognostic factor ([@b2-or-35-05-2592]). Residual micro-metastatic disease in the axillary lymph nodes after NAC is a worse prognostic factor than negative nodes in breast cancer ([@b3-or-35-05-2592]). Therefore, prediction of lymph node metastasis is important for prognosis and choosing an optimal therapeutic strategy for the treatment of breast cancer after NAC.

Previous reports have described predictive factors of complete pathological response in primary breast tumors after NAC ([@b4-or-35-05-2592]). Judgement of pathological therapeutic effects of breast cancer after NAC vary among studies ([@b5-or-35-05-2592]--[@b12-or-35-05-2592]). However, no article has described residual carcinoma patterns of the primary breast tumor to predict the presence or absence of lymph node metastasis. Therefore, we devised a classification system of three residual carcinoma patterns using a simple method based on cell density: dense, focal/nested, and sporadic/*in-situ*. In this study, we examined 50 cases of breast cancer and associated dissected lymph nodes after NAC and divided the cases into an eradicated lymph node group (14 cases), a residual lymph node group (26 cases), and a no change lymph node group (10 cases) to compare differences in the three residual carcinoma patterns in primary breast tumor between the eradicated lymph node and residual lymph node groups. Furthermore, we analyzed differences in clinicopathological factors in residual carcinoma patterns of the primary breast tumors.

Materials and methods
=====================

Patient samples
---------------

We retrospectively evaluated computed tomography (CT) or positron emission tomography-computed tomography (PET-CT) scans of 50 surgically resected breast cancer lesions taken before and after NAC between 2006 and 2015 at Hirosaki University Hospital (Hirosaki, Aomori, Japan). Informed consent was obtained from each patient regarding the use of clinical records and pathological specimens. Twenty-nine patients underwent total mastectomy, and 21 underwent partial mastectomy. Sentinel node biopsy was performed for 2 cases, level I lymph node dissection for 48 cases, level II lymph node dissection for 23 cases, level III lymph node dissection for 3 cases, and Rotter dissection for 2 cases. Chemotherapy regimens are shown in [Table I](#tI-or-35-05-2592){ref-type="table"}. The chemotherapy regimens were performed as follows: AC (doxorubicin + cyclophosphamide), 4 cases (8%); AC→T (doxorubicin + cyclophosphamide followed by taxane), 24 cases (48%); AC→T + HER (doxorubicin + cyclophosphamide followed by taxane + trastuzumab), 12 cases (24%); EC (epirubicin hydrochloride + cyclophosphamide hydrate), 2 cases (4%); EC→T (epirubicin hydrochloride + cyclophosphamide hydrate followed by taxane), 7 cases (14%); and TC (docetaxel + cyclophosphamide hydrate), 1 case (2%). The mean number of cycles per regimen was 7.66 (range, 4--8). Union for International Cancer Control (UICC) stages of before and after NAC are shown in [Table II](#tII-or-35-05-2592){ref-type="table"}. UICC clinical stages (cStage) before NAC were as follows: cStage 0, 0 cases (0%); cStage I, 2 cases (4%); cStage II, 26 cases (52%); and cStage III, 22 cases (44%). UICC cStages after NAC were as follows: cStage 0, 0 cases (0%); cStage I, 16 cases (32%); cStage II, 24 cases (48%); and cStage III, 9 cases (18%). UICC pathological stages (pStage) after NAC were as follows: pStage 0, 4 cases (8%); pStage I, 13 cases (26%); pStage II, 18 (36%); and pStage III, 15 cases (30%).

Pathological examinations of the primary tumors
-----------------------------------------------

Partial mastectomy specimens were sliced into 5 mm sections and total mastectomy specimens, which included the maximal tumor sectioned surface, were sliced as much as possible to distinguish the lesion. For histopathological examination, breast cancer specimens were routinely formalin-fixed, paraffin-embedded, thinly sectioned, and stained with hematoxylin and eosin. Carcinoma lesions were histologically graded according to the Bloom-Richardson system ([@b13-or-35-05-2592]). Tumor maximal invasion diameters were measured and the extent of lymphatic invasion, venous invasion and intraductal component was evaluated. The status of the estrogen receptor (ER), progesterone receptor (PgR), and HER2 was immunohistochemically detected. ER/PR expression was defined as positive when ≥10% of nuclei in the total tumor cells were stained. As to HER2: 1, negative, 2, uncertain, and 3, positive. Cancers with an HER2 score of 2+ were additionally evaluated using dual-color *in situ* hybridization. In this study, breast cancer was classified into four groups as follows: luminal A (ER and/PR-positive/HER2-negative/low Ki-67), luminal B (ER- and/or PR-positive/HER2-negative/high Ki-67), luminal B (ER- and/or PR-positive/HER2 overexpression/any Ki-67), HER2 (ER and PR absent/HER2 overexpression), and triple-negative (ER and PR absent/HER2-negative) ([@b14-or-35-05-2592]).

Residual carcinoma patterns
---------------------------

Whole sections examined in this study were divided into three residual carcinoma patterns: dense (tumor cell density remained in a very high state), focal/nested (tumor cells disappeared focally with fibrosis or granulation tissue or macrophage infiltration, or elastic fiber within the tumor area), and sporadic/*in situ* (a few cancer nests remained or *in situ* lesion only remained). If a biopsy was performed before chemotherapy, we compared the surgically resected specimen with its biopsy results as much as possible ([Fig. 1](#f1-or-35-05-2592){ref-type="fig"}). Forty biopsies of primary tumors before NAC were evaluated in this study. Focal/nested and sporadic/*in-situ* patterns were included in the non-dense group when we analyzed residual carcinoma patterns and clinicopathological factors.

Pathological examination of lymph nodes
---------------------------------------

We chose lymph nodes from 14 cases that were examined by fine needle aspiration biopsy cytology or core needle biopsy before NAC. Five cases that were positive by lymph node biopsy before NAC and in which lymph node metastasis disappeared after NAC were histologically examined in detail. Lymph nodes that were more than 5% fibrotic were defined as eradicated lymph nodes. We did not consider fibrosis of the lymph node capsule. We chose lymph node specimens with irregular fibrosis. The sections were scanned using light microscopy at a low magnification (×12.5 or ×40). The composition of the image was carried out in Adobe Photoshop (Adobe^®^ Photoshop^®^ CS2 Windows^®^ USA). The extent of fibrosis within the lymph nodes was measured using ImageJ software ([@b15-or-35-05-2592]). Three cases that were negative by lymph node biopsy before NAC and negative for lymph node metastasis after NAC were also histologically examined in detail. \'No change\' lymph nodes included those with few hemosiderin laden macrophages and no fibrosis.

Division of the eradicated and residual lymph node groups
---------------------------------------------------------

Fifty breast cancer cases after NAC were divided into an eradiated lymph node group, a residual lymph node group, and a no change lymph node group. The no change lymph node cases were excluded in this study. Differences in the three residual carcinoma patterns (dense, focal/nested, and sporadic/*in-situ*) between the eradiated lymph node and residual lymph node groups were examined.

Residual carcinoma patterns and clinicopathological factors
-----------------------------------------------------------

Residual carcinoma patterns were divided into two groups, a dense group and a non-dense group. Focal/nested and sporadic/*in-situ* patterns were defined as the non-dense group. Differences in the following clinicopathological factors between the dense and non-dense groups were examined: trastuzumab administration, reduced ratio on CT, primary tumor area before/after NAC on CT, intrinsic subtype, ER status, PgR status, HER2 status, Ki-67 labeling index, primary tumor pathological diameter, lymphatic invasion, venous invasion, histological grade, nuclear atypia, mitotic count, tubular formation, and extent of intraductal components. Primary breast tumor areas before and after NAC were calculated using DICOM data on CT images. The primary tumor area was calculated three times for each case and the mean value was used for analysis. The reduced ratio was calculated using the mean area of the primary breast tumor before and after NAC as follows: Reduced ratio = (1 - mean area after NAC/mean area before NAC) × 100.

Statistical analyses
--------------------

Statistical comparisons between two groups were analyzed using the Pearson\'s Chi-square test for categorical data and the Wilcoxon rank sum test for continuous data. Differences were considered to be statistically significant at a p-value of \<0.05. An adjusted residue of ±2 or more was considered to be significant. All statistical evaluations were performed using R (<http://www.r-project.org>) and IBM^®^ SPSS^®^ Statistics version 22 (IBM Corporation, Armonk, NY, USA) software.

Results
=======

Tumor characteristics
---------------------

Tumor characteristics are shown in [Table III](#tIII-or-35-05-2592){ref-type="table"}. Intrinsic subtype included: luminal A, 13 cases (26%); luminal B, 28 cases (56%); HER2 type, 4 cases (8%) and triple-negative, 5 cases (10%). Histology included: ductal carcinoma *in situ*, 4 cases (4%); invasive ductal carcinoma, 38 cases (76%); invasive lobular carcinoma, 4 cases (8%); invasive micropapillary carcinoma, 1 case (2%); mucinous carcinoma, 2 cases (4%) and intracystic papillary carcinoma, 1 case (2%). Lymph node status included: negative, 26 cases (52%) and positive, 24 cases (48%). Lymphatic invasion included: negative, 31 cases (62%) and positive, 19 cases (38%). Venous invasion included: negative, 46 cases (92%) and positive, 4 cases (8%). Histological grade included: I, 15 cases (30%); II, 27 cases (54%) and III, 8 cases (16%). Nuclear atypia included: 1, 3 cases (6%); 2, 27 cases (54%) and 3, 20 cases (40%). Mitotic count included: 1, 32 cases (64%); 2, 14 cases (28%) and 3, 4 cases (8%). Tubular formation included: 1, 1 case (2%); 2, 23 cases (46%) and 3, 26 cases (52%). Extensive intraductal components included: negative, 38 cases (76%) and positive, 12 cases (24%).

Eradicated lymph node
---------------------

Fine needle aspiration biopsy cytology or core needle biopsy of five eradicated lymph node cases performed before NAC showed fibrosis within the lymph nodes. The percentage of fibrosis of the five lymph nodes was 34.6, 19.8, 14.0, 9.6, and 5.3%, respectively. A representative specimen of an eradicated lymph node with 19.8% fibrosis within the lymph node is shown in [Fig. 2](#f2-or-35-05-2592){ref-type="fig"}. Three cases with lymph nodes negative before NAC and no lymph node metastasis after NAC had only a few hemosiderin laden macrophages and no fibrosis ([Fig. 3](#f3-or-35-05-2592){ref-type="fig"}). These lymph nodes were classified as no change lymph nodes.

Residual carcinoma patterns and lymph node metastasis of the eradicated and residual lymph node groups
------------------------------------------------------------------------------------------------------

There were significant differences in the residual patterns (P=0.0034) between the eradicated and residual lymph node groups as many of the residual lymph nodes had dense patterns (adjusted residue +2.3) and many of the eradicated lymph nodes had sporadic/*in-situ* patterns (adjusted residue +2.9) ([Table IV](#tIV-or-35-05-2592){ref-type="table"}).

Residual carcinoma patterns and clinicopathological factors
-----------------------------------------------------------

Clinicopathological factors of the non-dense and dense group are shown in [Table V](#tV-or-35-05-2592){ref-type="table"}. The dense group had a higher reduced ratio (P\<0.001), larger area before NAC (P=0.003), and larger area after NAC (P\<0.00001), as compared with the non-dense group. There were significant differences in the intrinsic subtype (P=0.004) between groups. Particularly, there were a larger number of triple-negative cases in the dense group (adjusted residue +3.6). The Ki-67 labeling index was higher in the dense group (P=0.006) than that in the non-dense group. Pathological tumor diameter was larger in the dense group (P=0.010) than that in the non-dense group. The histological grade (P=0.016) and mitotic count (P=0.004) were higher, and tubular formation (P=0.027) was less frequent in the dense group than that in the non-dense group. There were no significant differences in age (P=0.567), trastuzumab administration (P=0.304), ER (P=0.105), PgR (P=0.266), HER2 status (P=0.098), lymphatic invasion (P=0.143), venous invasion (P=0.075), nuclear atypia (P=0.616), or extensive intraductal component (P=1.00) between the dense and non-dense groups.

Discussion
==========

The results of this study suggest that residual carcinoma patterns (dense, focal/nested, and sporadic/*in-situ*) in primary breast cancer after NAC are correlated with lymph node metastasis status. There was a high incidence of dense patterns in the residual lymph node group and a high incidence of sporadic/*in-situ* patterns in the eradicated lymph node group. The dense group had malignant potential of breast cancer after NAC when compared with the non-dense group. The tumor areas before and after NAC were larger in the dense group than that in the non-dense group. The Ki-67 labeling index, histological grade, mitotic count, and extent of tubular formation were higher in the dense group than these parameters in the non-dense group. Interestingly, the tumor reduced ratio after NAC was larger in the dense group than that in the non-dense group.

The \'dense\' residual carcinoma pattern was associated with the potential for residual carcinoma in the lymph nodes. No previous report has predicted lymph node metastasis in breast cancer after NAC using residual carcinoma patterns. The Miller and Payne system is used to assess the response to chemotherapy based on a 5-point histological grading system of fundamental features that include reduction in tumor cellularity and comparisons with pre-treatment core biopsies. This grading system is correlated with overall survival and disease-free survival ([@b16-or-35-05-2592]). The Millar and Payne system and our proposed histological classification system suggest that tumor cellularity is the most important characteristic to assess the response to NAC in breast cancer. Rajan *et al* also reported that cellularity was useful to assess the pathologic responses of breast cancer to chemotherapy ([@b17-or-35-05-2592]). A \'dense\' residual carcinoma pattern has malignant potential after NAC in breast cancer. Resistance of tumor cells to chemotherapy is suggested by a high Ki-67 labeling index, high mitotic count, and large tumor area. A dense pattern is associated with a high histological grade due to a high mitotic count and less tubular formation.

A residual carcinoma pattern is based on a very simple criteria of tumor cell density and change in histological degeneration but is not dependent on tumor area before NAC. Therefore, it is easy to predict the therapeutic effect using histological diagnosis without image analysis. It is possible to recognize the presence of a dense pattern using core needle biopsy after NAC; therefore, it may be possible to predict lymph node metastasis before surgery by core needle biopsy using our proposed residual carcinoma patterns.

This new classification system considers only three patterns. Although a relatively small number of cases were analyzed, the focal/nested pattern demonstrated wide range chemotherapy responses. By analyzing a larger number of cases in the future, focal/nested cases can be divided into two groups, i.e., focal/nested low and high. This study was a small-scale analysis carried out at a single institution, and there was difficulty with the unified chemotherapy regimen. Before NAC, the prediction of the presence or absence of lymph node metastasis was dependent only on imaging and sometimes after starting treatment. The findings of this study were derived from detailed histopathological analyses of primary breast tumors and associated dissected lymph nodes after NAC. Therefore, these results were realistic and may be useful to predict lymph node metastasis after NAC. Further identification of lymph node metastasis predictors is expected by the additional accumulation of cases in the future.

The results of this study suggest that a residual carcinoma pattern may be predictive of lymph node metastasis after NAC in breast cancer and a dense residual carcinoma pattern of a primary breast tumor after NAC may be an indicator of therapeutic resistance to NAC.
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![(A, C, E and G) Core needle biopsy before neoadjuvant chemotherapy (NAC). (B, D, F and H) Surgical specimens of the same case as the left photograph. (A and B) This case was classified as dense since cancer cell density was very high in the surgical specimen. Histologically, there was no therapeutic effect observed. (C and D) This case was classified as focal/nested. Hemosiderin laden macrophages were noted in the stroma (arrowhead), but cancer cell density was still high. (E and F) This case was classified as sporadic as a few cancer nests were present (arrows). (G and H) This case was classified as *in situ* as only a non-invasive ductal component was present.](OR-35-05-2592-g00){#f1-or-35-05-2592}

![(A) ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT) before neoadjuvant chemotherapy (NAC). Lymph node metastasis was observed using PET-CT. Lymph node metastasis was confirmed using core needle biopsy before NAC in this case. (B) PET-CT after NAC, no lymph node metastasis was observed on PET-CT. (C) Irregular fibrosis of 19.8% is noted within the lymph node, as measured using ImageJ software.](OR-35-05-2592-g01){#f2-or-35-05-2592}

![(A) Enhanced computed tomography (CT) before neoadjuvant chemotherapy (NAC). This case was suspected as lymph node metastasis using imaging. There was no carcinoma metastasis by fine needle aspiration biopsy cytology before NAC. (B) Enhanced CT after NAC. The lymph node was smaller than before NAC. (C) A few hemosiderin laden macrophages are noted in the negative lymph node (arrowhead). (D) There is no apparent fibrosis in the lymph node. This lymph node was classified as a \'no change\' lymph node.](OR-35-05-2592-g02){#f3-or-35-05-2592}

###### 

Chemotherapy regimens and cycles.

  Chemotherapy regimen   n (%)
  ---------------------- -------------
  AC                     4 (8)
  AC→T                   24 (48)
  AC→T + HER             12 (24)
  EC                     2 (4)
  EC→T                   7 (14)
  TC                     1 (2)
  Mean cycles (range)    7.66 (4--8)

AC, doxorubicin + cyclophosphamide; AC→T, doxorubicin + cyclophosphamide followed by taxane; AC→T + HER, doxorubicin + cyclophosphamide followed by taxane + trastuzumab; EC, epirubicin hydrochloride + cyclophosphamide hydrate; EC→T, epirubicin hydrochloride + cyclophosphamide hydrate followed by taxane; TC, docetaxel + cyclophosphamide hydrate.

###### 

UICC stage before and after NAC.

              UICC cStage before NAC n (%)   UICC cStage after NAC n (%)   UICC pStage after NAC n (%)
  ----------- ------------------------------ ----------------------------- -----------------------------
  Stage 0     0 (0)                          0 (0)                         4 (8)
  Stage I     2 (4)                          16 (32)                       13 (26)
  Stage II    26 (52)                        24 (48)                       18 (36)
  Stage III   22 (44)                        9 (18)                        15 (30)

UICC, Union for International Cancer Control; cStage, clinical stage; pStage, pathological stage; NAC, neoadjuvant chemotherapy.

###### 

Histological findings of the surgical resection specimens after neoadjuvant chemotherapy.

  Features                             n=50 (100%)
  ------------------------------------ -------------
  Intrinsic subtype                    
   Luminal A                           13 (26)
   Luminal B                           28 (56)
   HER2                                4 (8)
   Triple-negative                     5 (10)
  Histology                            
   Ductal carcinoma *in situ*          4 (4)
   Invasive ductal carcinoma           38 (76)
   Invasive lobular carcinoma          4 (8)
   Invasive micropapillary carcinoma   1 (2)
   Mucinous carcinoma                  2 (4)
   Intracystic papillary carcinoma     1 (2)
  Lymph node status                    
   Negative                            26 (52)
   Positive                            24 (48)
  Lymphatic invasion                   
   Negative                            31 (62)
   Positive                            19 (38)
  Venous invasion                      
   Negative                            46 (92)
   Positive                            4 (8)
  Histological grade                   
   I                                   15 (30)
   II                                  27 (54)
   III                                 8 (16)
  Nuclear atypia                       
   1                                   3 (6)
   2                                   27 (54)
   3                                   20 (40)
  Mitotic count                        
   1                                   32 (64)
   2                                   14 (28)
   3                                   4 (8)
  Tubular formation                    
   1                                   1 (2)
   2                                   23 (46)
   3                                   26 (52)
  Extensive intraductal component      
   Negative                            38 (76)
   Positive                            12 (24)

###### 

Residual carcinoma patterns in primary breast tumors and lymph node metastasis.

  Residual carcinoma pattern   Residual lymph node group (n=26) (100%) n (%)            Eradicated lymph node group (n=14) (100%) n (%)         P-value
  ---------------------------- -------------------------------------------------------- ------------------------------------------------------- ---------
  Dense                        11 (42.3)[a](#tfn3-or-35-05-2592){ref-type="table-fn"}   1 (7.1)[b](#tfn4-or-35-05-2592){ref-type="table-fn"}    0.003
  Focal/nested                 15 (57.7)                                                9 (64.3)                                                
  Sporadic/*in-situ*           0 (0)[b](#tfn4-or-35-05-2592){ref-type="table-fn"}       4 (28.6)[a](#tfn3-or-35-05-2592){ref-type="table-fn"}   

Adjusted residues \>2

adjusted residues ≤2.

###### 

Clinicopathological factors of the non-dense and dense group.

                         Non-dense (n=35) (100%) n (%)                            Dense (n=15) (100%) n (%)                                P-value
  ---------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Age (mean, years)      50.6                                                     49.0                                                     0.567
  Trastuzumab                                                                                                                              
   On                    10 (28.6)                                                2 (13.3)                                                 0.304
   Off                   25 (71.4)                                                13 (86.7)                                                
  Reduced ratio          0.089                                                    0.496                                                    \<0.001[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
   Area before NAC       336.5 mm^2^                                              1014.0 mm^2^                                             0.003[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
   Area after            33.6 mm^2^                                               213.7 mm^2^                                              \<0.00001[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
  Intrinsic subtype                                                                                                                        
   Luminal A             10 (28.6)                                                3 (20.0)                                                 0.004[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
   Luminal B             21 (60.0)                                                7 (46.7)                                                 
   HER2                  4 (11.4)                                                 0 (0)                                                    
   Triple-negative       0 (0)[c](#tfn7-or-35-05-2592){ref-type="table-fn"}       5 (33.3)[b](#tfn6-or-35-05-2592){ref-type="table-fn"}    
  ER status                                                                                                                                
   Positive              31 (88.6)                                                10 (66.7)                                                0.105
   Negative              4 (11.4)                                                 5 (33.3)                                                 
  PgR status                                                                                                                               
   Positive              20 (57.1)                                                6 (40.0)                                                 0.266
   Negative              15 (42.9)                                                9 (60.0)                                                 
  HER2 status                                                                                                                              
   Positive              14 (40.0)                                                2 (13.3)                                                 0.098
   Negative              21 (60.0)                                                13 (86.7)                                                
  Ki-67 labeling index   5                                                        50                                                       0.006[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
  Tumor diameter (mm)    11                                                       30                                                       0.010[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
  Lymphatic invasion                                                                                                                       
   Positive              11 (31.4)                                                8 (53.3)                                                 0.143
   Negative              24 (68.6)                                                7 (46.7)                                                 
  Venous invasion                                                                                                                          
   Positive              1 (2.9)                                                  3 (20.0)                                                 0.075
   Negative              34 (97.1)                                                12 (80.0)                                                
  Histological grade                                                                                                                       
   I                     14 (40.0)[b](#tfn6-or-35-05-2592){ref-type="table-fn"}   1 (6.7)[c](#tfn7-or-35-05-2592){ref-type="table-fn"}     0.016[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
   II                    18 (51.4)                                                9 (60.0)                                                 
   III                   3 (8.6)[c](#tfn7-or-35-05-2592){ref-type="table-fn"}     5 (33.3)[b](#tfn6-or-35-05-2592){ref-type="table-fn"}    
  Nuclear atypia                                                                                                                           
   1                     3 (8.6)                                                  0 (0)                                                    0.616
   2                     19 (54.3)                                                8 (53.3)                                                 
   3                     13 (37.1)                                                7 (46.7)                                                 
  Mitotic count                                                                                                                            
   1                     26 (74.3)[b](#tfn6-or-35-05-2592){ref-type="table-fn"}   6 (40.0)[c](#tfn7-or-35-05-2592){ref-type="table-fn"}    0.004[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
   2                     9 (25.7)                                                 5 (33.3)                                                 
   3                     0 (0)[c](#tfn7-or-35-05-2592){ref-type="table-fn"}       4 (26.7)[b](#tfn6-or-35-05-2592){ref-type="table-fn"}    
  Tubular formation                                                                                                                        
   1                     1 (2.9)                                                  0 (0)                                                    0.027[a](#tfn5-or-35-05-2592){ref-type="table-fn"}
   2                     20 (57.1)[b](#tfn6-or-35-05-2592){ref-type="table-fn"}   3 (20.0)[c](#tfn7-or-35-05-2592){ref-type="table-fn"}    
   3                     14 (40.0)[c](#tfn7-or-35-05-2592){ref-type="table-fn"}   12 (80.0)[b](#tfn6-or-35-05-2592){ref-type="table-fn"}   
  EIC                                                                                                                                      
   Positive              9 (25.7%)                                                3 (20.0%)                                                1.00
   Negative              26 (74.3%)                                               12 (80.0%)                                               

P\<0.05.

adjusted residue \>2

adjusted residue \<-2. NAC, neoadjuvant chemotherapy; ER, estrogen receptor; PgR, progesterone receptor; EIC, extensive intraductal component. All data values are expressed in n (%) except for age, reduced ratio, area before/after NAC, Ki-67 labeling index and tumor diameter.
